Initial Statement of Beneficial Ownership (3)
April 02 2020 - 7:30PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Sukhija Remy |
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/1/2020
|
3. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [MDGL]
|
|
(Last)
(First)
(Middle)
FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE, SUITE 200 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
SVP and Chief Comm'l Officer / |
|
(Street)
WEST CONSHOHOCKEN, PA 19428
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | 4/1/2020 (1) | 4/1/2030 | Common Stock | 60000 | $60.26 | D | |
| Explanation of Responses: |
| (1) | The option vests as to 25% of the underlying Common Stock on the first anniversary of the date of grant (April 1, 2021) and thereafter as to 6.25% of the underlying Common Stock on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Sukhija Remy
FOUR TOWER BRIDGE
200 BARR HARBOR DRIVE, SUITE 200
WEST CONSHOHOCKEN, PA 19428 |
|
| SVP and Chief Comm'l Officer |
|
Signatures
|
| /s/ Brian Lynch, as Attorney- In-Fact for Remy Sukhija | | 4/2/2020 |
| **Signature of Reporting Person | Date |
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
